Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07538960

Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.

Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital México

San José, Uruca, 10107, Costa Rica

Location contact

Daniel Barquero-Orias, Dermatologist

CONTACT

[email protected]

+506 83411026

Daniel Barquero-Orias, Dermatologist

SUB_INVESTIGATOR

Raquel Ramirez-Fallas, Dermatology Resident

PRINCIPAL_INVESTIGATOR

Said Fallas-Moya, Dermatologist

SUB_INVESTIGATOR

About this study

This retrospective observational study will analyze adult patients (≥18 years) with a confirmed diagnosis of cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México between January 2019 and December 2025. Data will be obtained from electronic medical records (EDUS), including sociodemographic characteristics, clinical presentation, histopathological and immunohistochemical findings, disease staging, treatment modalities, and clinical outcomes.

Patients must have at least one documented dermatological evaluation and have received treatment, including skin-directed therapies and/or systemic therapies. Records that are incomplete, inconsistent, or lack histopathological confirmation will be excluded.

The study aims to characterize local epidemiological and therapeutic patterns and describe clinical outcomes using descriptive statistical analysis, providing updated real-world evidence to support clinical decision-making and optimize management strategies for cutaneous T-cell lymphoma in a national referral center.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.
  • Patients aged 18 years or older, of both sexes.
  • Patients with at least one dermatological evaluation recorded during the study period.
  • Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments.

Exclusion criteria

  • Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.
  • Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.
  • Duplicate or inconsistent records that hinder the correct identification and classification of the patient.
  • Patients attended outside the established study period.
  • Patients outside the age range.
  • Patients who do not belong to the Dermatology Service of Hospital México.

Treatment and study plan

Primary outcomes

  1. Characterize the epidemiology

    Time frame: 2019-2025

    Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México.

  2. Characterize the therapeutic management

    Time frame: 2019-2025.

    Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México

Secondary outcomes

  1. Describe the sociodemographic/epidemiological characteristics

    Time frame: 2019-2025

    To describe the sociodemographic and epidemiological characteristics of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México during the period from 2019 to 2025.

  2. Classify the clinical manifestations/clinical subtypes

    Time frame: 2019-2025

    Classify the clinical manifestations and clinical subtypes of cutaneous T-cell lymphoma present in the studied population.

  3. Identify the histopathological/ immunohistochemical findings

    Time frame: 2019-2025

    To identify the histopathological and immunohistochemical findings associated with cutaneous T-cell lymphoma in the included patients.

  4. Analyze the therapeutic management modalities.

    Time frame: 2019-2025

    Analyze the therapeutic management modalities used, including skin-directed therapies and their outcomes.

  5. identify the clinical stage at the time of diagnosis

    Time frame: 2019-2025

    identify the clinical stage of the disease at the time of diagnosis according to the TNMB staging system.

  6. Evaluation of imaging studies and laboratory.

    Time frame: 2019-2025

    Evaluate imaging studies and laboratory findings of patients with cutaneous T-cell lymphoma during the follow-up period.

  7. Evaluation of clinical course and outcomes.

    Time frame: 2019-2025

    Evaluation of clinical course and outcomes of patients with cutaneous T-cell lymphoma during the follow-up period.

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel Barquero-Orias, Dermatologist

CONTACT

[email protected]

+506 83411026

Sponsors and collaborators

Lead sponsor

Caja Costarricense de Seguro Social

Other Gov

Registry information

Official study title

Epidemiological Profile and Therapeutic Management of Patients Diagnosed With Cutaneous T-cell Lymphoma Evaluated in the Dermatology Department of Hospital México During the Period From 2019 to 2025.

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Apr 20, 2026
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.